Utilising Gamma-Delta T Cells to Mitigate Against Graft vs Host Disease

Time: 11:40 am
day: Day One


  • Maximising the inherent benefits of γδT cells to avoid patient immune rejection
  • Employing γδT cell receptors to target solid tumours without HLA
  • Unlocking efficient large-scale manufacturing of a T cell subpopulation to generate allogeneic therapies